99.98
-1.54(-1.52%)
Currency In USD
| Previous Close | 101.52 |
| Open | 102.36 |
| Day High | 103 |
| Day Low | 97.85 |
| 52-Week High | 121.21 |
| 52-Week Low | 11.07 |
| Volume | 248,288 |
| Average Volume | 766,065 |
| Market Cap | 2.54B |
| PE | -13.1 |
| EPS | -7.63 |
| Moving Average 50 Days | 77.94 |
| Moving Average 200 Days | 41.44 |
| Change | -1.54 |
If you invested $1000 in Cidara Therapeutics, Inc. (CDTX) 10 years ago, it would be worth $335.73 as of October 20, 2025 at a share price of $99.98. Whereas If you bought $1000 worth of Cidara Therapeutics, Inc. (CDTX) shares 5 years ago, it would be worth $1,671.91 as of October 20, 2025 at a share price of $99.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
GlobeNewswire Inc.
Oct 13, 2025 12:00 PM GMT
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
GlobeNewswire Inc.
Oct 10, 2025 12:00 PM GMT
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breakin
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
GlobeNewswire Inc.
Oct 09, 2025 12:00 PM GMT
Breakthrough Therapy designation comes in addition to previously awarded Fast Track designationSAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform